PTN Palatin (PTN) is flying under the radar, but it’s about to explode. Here’s why:
🔑 Catalysts for massive upside:
Bremelanotide (PTN’s lead drug) is advancing through FDA stages.
Major pharma partnerships are forming.
M&A potential – PTN could be a buyout target.
💰 Price Targets:
– Short-term: $3.50
– Mid-term (2025): $7.50–$10.00
Don’t miss out – this is a game-changer.
📩 Reach out via Telegram: ( i. v. a. n. p. a. t. r. i. c. e )